FR21C1018I1 - Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide - Google Patents

Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide

Info

Publication number: FR21C1018I1
Authority: FR; France
Prior art keywords: difluorobenzo; cyclopropanecarboxamide; dioxol; dihydroxypropyl; methylpropane
Prior art date: 2010-03-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1018C

Other languages

English (en)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-25

Filing date

2021-05-14

Publication date

2021-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-05-14 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2021-07-02 Publication of FR21C1018I1 publication Critical patent/FR21C1018I1/fr

2023-02-17 Application granted granted Critical

2023-02-17 Publication of FR21C1018I2 publication Critical patent/FR21C1018I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Obesity (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)

FR21C1018C 2010-03-25 2021-05-14 Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide Active FR21C1018I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US31737610P	2010-03-25	2010-03-25
US31995310P	2010-04-01	2010-04-01
US32163610P	2010-04-07	2010-04-07
US32156110P	2010-04-07	2010-04-07
EP11713134.2A EP2563778B1 (fr)	2010-03-25	2011-03-25	Forme cristalline de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
PCT/US2011/030032 WO2011119984A1 (fr)	2010-03-25	2011-03-25	Formes solides de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide

Publications (2)

Publication Number	Publication Date
FR21C1018I1 true FR21C1018I1 (fr)	2021-07-02
FR21C1018I2 FR21C1018I2 (fr)	2023-02-17

Family

ID=43903962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1018C Active FR21C1018I2 (fr)	2010-03-25	2021-05-14	Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide

Country Status (26)

Country	Link
US (1)	US20110251253A1 (fr)
EP (5)	EP2826776B1 (fr)
JP (5)	JP5734410B2 (fr)
CN (3)	CN109081804B (fr)
AU (3)	AU2011230508B2 (fr)
BR (1)	BR112012024338B1 (fr)
CA (2)	CA3016080C (fr)
CY (3)	CY1123794T1 (fr)
DK (1)	DK2826776T3 (fr)
ES (4)	ES2604105T3 (fr)
FR (1)	FR21C1018I2 (fr)
HR (2)	HRP20230661T1 (fr)
HU (3)	HUE052759T2 (fr)
IL (4)	IL222117B (fr)
LT (2)	LT2826776T (fr)
LU (1)	LUC00207I2 (fr)
MX (3)	MX347804B (fr)
NO (1)	NO2021021I1 (fr)
NZ (3)	NZ700556A (fr)
PL (2)	PL2826776T3 (fr)
PT (1)	PT2826776T (fr)
RS (1)	RS61314B1 (fr)
RU (1)	RU2711481C2 (fr)
SI (1)	SI2826776T1 (fr)
SM (1)	SMT202100051T1 (fr)
WO (1)	WO2011119984A1 (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
NZ587549A (en)	2004-06-24	2012-10-26	Vertex Pharma	6-Amino-indole derivatives and processes for their preparation
EP1912983B1 (fr)	2005-08-11	2011-06-08	Vertex Pharmaceuticals, Inc.	Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
KR101331768B1 (ko) *	2005-11-08	2013-11-22	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
CA2635581C (fr)	2005-12-28	2017-02-28	Vertex Pharmaceuticals Incorporated	Formes solides de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide
CA2856037C (fr)	2005-12-28	2017-03-07	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs a cassette liant l'atp
PL2674428T3 (pl)	2006-04-07	2017-01-31	Vertex Pharmaceuticals Incorporated	Modulatory transporterów z kasetą wiążącą ATP
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CA2686838C (fr)	2007-05-09	2017-03-14	Vertex Pharmaceuticals Incorporated	Modulateurs de cftr
AU2008302598B2 (en)	2007-08-24	2014-07-17	Vertex Pharmaceuticals Incorporated	Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis
SI2578571T1 (sl)	2007-11-16	2016-01-29	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
DK2639223T3 (en)	2007-12-07	2017-06-19	Vertex Pharma	Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
HRP20170241T2 (hr)	2007-12-07	2023-03-17	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ736561A (en)	2008-02-28	2018-02-23	Vertex Pharma	Heteroaryl derivatives as cftr modulators
DK2615085T3 (en)	2008-03-31	2015-10-05	Vertex Pharma	Pyridyl derivatives as CFTR modulators
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US8716338B2 (en)	2008-09-29	2014-05-06	Vertex Pharmaceuticals Incorporated	Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
PL2408750T3 (pl)	2009-03-20	2016-02-29	Vertex Pharma	Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS54783B1 (sr)	2010-04-07	2016-10-31	Vertex Pharma	Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
CA2797118C (fr) *	2010-04-22	2021-03-30	Vertex Pharmaceuticals Incorporated	Procede de production de composes de cycloalkylcarboxamido-indole
US8563593B2 (en) *	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
MX357328B (es)	2011-11-08	2018-07-05	Vertex Pharma	Moduladores de trasportadores de casete enlazante de atp.
US20130172375A1 (en) *	2011-12-13	2013-07-04	Hoffmann-La Roche Inc.	Pharmaceutical composition
AU2013226076B2 (en)	2012-02-27	2017-11-16	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2872122A1 (fr)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
EP2968323A4 (fr)	2013-03-13	2016-12-14	Flatley Discovery Lab	Composés de pyridazinone et procédés pour le traitement de fibrose kystique
CN104415345A (zh) *	2013-08-30	2015-03-18	天津药物研究院	一种多元复合物及其制备方法
RU2718044C2 (ru)	2013-11-12	2020-03-30	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
RS62140B1 (sr)	2014-04-15	2021-08-31	Vertex Pharma	Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
IL313498A (en)	2014-10-06	2024-08-01	Vertex Pharma	Modulators of the cystic fibrosis transmembrane conductance regulator
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
MY194313A (en) *	2014-10-31	2022-11-27	Galapagos Nv	Substituted chromanes and method of use
HRP20211194T1 (hr)	2014-11-18	2021-10-29	Vertex Pharmaceuticals Inc.	Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
WO2016109362A1 (fr)	2014-12-31	2016-07-07	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamides comme modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
AU2016243171B2 (en)	2015-03-31	2020-10-08	Concert Pharmaceuticals, Inc.	Deuterated VX-661
CN105130949B (zh) *	2015-09-02	2019-01-29	阜新奥瑞凯新材料有限公司	1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法
WO2017180794A1 (fr)	2016-04-13	2017-10-19	Skyline Antiinfectives, Inc.	Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
HUP1600270A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HRP20211683T1 (hr)	2016-09-30	2022-03-04	Vertex Pharmaceuticals Incorporated	Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora
US10399940B2 (en) *	2016-10-07	2019-09-03	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
MX2021013639A (es)	2016-12-09	2022-09-30	Vertex Pharma	Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20210069174A1 (en)	2017-07-01	2021-03-11	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of cystic fibrosis
US20200171015A1 (en)	2017-07-17	2020-06-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
AU2018304168B2 (en)	2017-07-17	2023-05-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
WO2019079760A1 (fr)	2017-10-19	2019-04-25	Vertex Pharmaceuticals Incorporated	Formes cristallines et compositions de modulateurs de cftr
CN107880011B (zh) *	2017-11-27	2019-08-16	山东省医学科学院药物研究所	鲁玛卡托关键中间体的合成方法
US20210228489A1 (en)	2017-12-04	2021-07-29	Vertex Pharmaceuticals Incorporated	Compositions for treating cystic fibrosis
US11465985B2 (en)	2017-12-08	2022-10-11	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt)	2018-02-15	2023-04-11	Vertex Pharmaceuticals Incorporated	Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
CN110193012B (zh) *	2018-02-27	2022-02-08	江苏恒瑞医药股份有限公司	一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
WO2019195739A1 (fr)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2019200246A1 (fr)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
RS64192B9 (sr)	2018-11-14	2025-10-31	Vertex Pharma	Metode lečenja cistične fibroze
CA3067611A1 (fr)	2019-01-15	2020-07-15	Apotex Inc.	Procede de preparation de tezacaftor et intermediaires connexes
UY38630A (es)	2019-04-03	2020-10-30	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (fr)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Formes solides de modulateurs de cftr
UY38696A (es)	2019-05-14	2020-11-30	Vertex Pharma	Moduladores de alfa-1 antitripsina
WO2020242935A1 (fr)	2019-05-29	2020-12-03	Vertex Pharmaceuticals Incorporated	Méthodes de traitement de la mucoviscidose
EP4013760A1 (fr)	2019-08-14	2022-06-22	Vertex Pharmaceuticals Incorporated	Formes cristallines de modulateurs de cftr
MX2022001827A (es)	2019-08-14	2022-06-09	Vertex Pharma	Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
US11584761B2 (en)	2019-08-14	2023-02-21	Vertex Pharmaceuticals Incorporated	Process of making CFTR modulators
WO2021140525A1 (fr) *	2020-01-07	2021-07-15	Msn Laboratories Private Limited, R&D Center	Nouvelle forme cristalline de 1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl}cyclopropane-1-carboxamide et son procédé de préparation
EP4114832A1 (fr)	2020-03-06	2023-01-11	Química Sintética, S.A.	Formes solides de tezacaftor et leurs procédés de préparation
WO2022194399A1 (fr)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles en tant que modulateurs de cftr
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230303589A1 (en)	2020-08-13	2023-09-28	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
WO2022076626A1 (fr)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
EP4225764A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
EP4225762A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225765A2 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
EP4225737A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
AU2021356651A1 (en)	2020-10-07	2023-05-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
KR20230110313A (ko)	2020-11-17	2023-07-21	버텍스 파마슈티칼스 인코포레이티드	4-(5-(4-플루오로페닐)-6-(테트라하이드로-2H-피란-4-일)-1,5-디하이드로피롤로[2,3-f]인다졸-7-일)벤조산의 고형분 형태
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en)	2020-12-10	2023-07-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
KR20240155228A (ko)	2022-02-03	2024-10-28	버텍스 파마슈티칼스 인코포레이티드	(6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
IL314449A (en)	2022-02-03	2024-09-01	Vertex Pharma	Methods of treatment for cystic fibrosis
CN118974059A (zh)	2022-02-08	2024-11-15	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
GEAP202516620A (en)	2022-04-06	2025-04-10	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
CN119947720A (zh)	2022-05-16	2025-05-06	弗特克斯药品有限公司	治疗囊性纤维化的方法
JP2025517323A (ja)	2022-05-16	2025-06-05	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒモジュレーターとしての大環状化合物の固体形態及びその調製
EP4565212A1 (fr)	2022-08-04	2025-06-11	Vertex Pharmaceuticals Incorporated	Compositions pour le traitement de maladies médiées par cftr
TW202421636A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	(3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
CN119907667A (zh)	2022-09-15	2025-04-29	爱杜西亚药品有限公司	大环cftr调节剂与cftr校正剂和/或cftr增效剂的组合
CN119894906A (zh)	2022-09-15	2025-04-25	爱杜西亚药品有限公司	大环cftr调节剂
WO2025076240A1 (fr)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Formes solides de modulateurs du régulateur de la perméabilité transmembranaire de la fibrose kystique
WO2025076235A1 (fr)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2025166342A1 (fr)	2024-02-04	2025-08-07	Vertex Pharmaceuticals Incorporated	Combinaison de vanzacaftor, de tezacaftor et de deutivacaftor destinée à être utilisée dans le traitement de la fibrose kystique
EP4648753A1 (fr)	2024-02-07	2025-11-19	Vertex Pharmaceuticals Incorporated	Compositions pour le traitement de maladies médiées par cftr
WO2025186214A1 (fr)	2024-03-05	2025-09-12	Idorsia Pharmaceuticals Ltd	Modulateurs de cftr macrocycliques

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
PT901786E (pt) *	1997-08-11	2007-08-07	Pfizer Prod Inc	Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
NZ521192A (en) *	2000-03-09	2005-01-28	Ono Pharmaceutical Co	Indole derivatives, process for preparation of the same and use thereof
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US20060083784A1 (en) *	2002-08-07	2006-04-20	Smithkline Beecham Corporation	Amorphous pharmaceutical compositions
CA2500498C (fr)	2002-09-30	2012-08-21	The Regents Of The University Of California	Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations
JP2004131393A (ja) *	2002-10-08	2004-04-30	Kowa Co	易溶出性製剤
WO2004080972A1 (fr)	2003-03-12	2004-09-23	Vertex Pharmaceuticals Incorporated	Pyrazoles, modulateurs de transporteurs de cassettes de liaison a l'atp
US6992096B2 (en)	2003-04-11	2006-01-31	Ptc Therapeutics, Inc.	1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2004110352A2 (fr)	2003-05-16	2004-12-23	The Regents Of The University Of California	Composes accroissant le transport d'ions par des cftr de mutants, et leurs utilisations
ATE440825T1 (de)	2003-06-06	2009-09-15	Vertex Pharma	Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
US7598412B2 (en)	2003-10-08	2009-10-06	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
JP4869072B2 (ja)	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
US7414037B2 (en)	2004-03-30	2008-08-19	The Regents Of The University Of California	Hydrazide-containing CFTR inhibitor compounds and uses thereof
AU2005251745A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2006044456A1 (fr)	2004-10-13	2006-04-27	Ptc Therapeutics, Inc.	Composes de suppression de non-sens et procedes de leur utilisation
EP1865949B1 (fr)	2005-03-11	2012-11-14	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs de cassette de liaison à l'ATP
JP2008538107A (ja)	2005-03-18	2008-10-09	ザリージェンツオブザユニバーシティオブカリフォルニア	変異型ｃｆｔｒプロセシングの修正において活性を有する化合物及びその用途
PT1874306E (pt)	2005-04-08	2012-10-11	Ptc Therapeutics Inc	Composições de um 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações sem sentido (ou nonsense)
ATE533749T1 (de)	2005-05-24	2011-12-15	Vertex Pharma	Modulatoren von atp-bindenden kassettentransportern
ES2367844T3 (es) *	2005-08-11	2011-11-10	Vertex Pharmaceuticals, Inc.	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
SI1926476T1 (sl) *	2005-08-29	2013-07-31	Sanofi-Aventis U.S. Llc	Amorfne trdne disperzije 7-kloro-N,N,5-trimetil-4-okso-3-fenil-3,5- dihidro-4H-piridazino/4,5-b/indol-1-acetamida
KR20080064971A (ko)	2005-10-06	2008-07-10	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ-결합 카세트 전달체의 조절자
NZ571934A (en) *	2006-03-20	2012-05-25	Vertex Pharma	Methods of spray drying formulations of vx-950 (telaprevir)
AU2007226983A1 (en) *	2006-03-20	2007-09-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions
PL2674428T3 (pl) *	2006-04-07	2017-01-31	Vertex Pharmaceuticals Incorporated	Modulatory transporterów z kasetą wiążącą ATP
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
WO2008064259A2 (fr) *	2006-11-21	2008-05-29	Biokey, Inc.	Composition de dispersion solide
JP5479912B2 (ja) *	2007-11-22	2014-04-23	全薬工業株式会社	複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法
HRP20170241T2 (hr) *	2007-12-07	2023-03-17	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
BRPI0823228B8 (pt) *	2008-11-06	2021-05-25	Vertex Pharmaceuticals Incorporarted	moduladores de cassete de ligação a atp
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
AU2010310449A1 (en) *	2009-10-22	2012-05-03	Vertex Pharmaceuticals Incorporated	Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011133953A1 (fr) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Compositions pharmaceutiques et leurs administrations
CA2797118C (fr) *	2010-04-22	2021-03-30	Vertex Pharmaceuticals Incorporated	Procede de production de composes de cycloalkylcarboxamido-indole
BR112013004443A8 (pt) *	2010-08-23	2018-01-02	Vertex Pharma	composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas

2011
- 2011-03-25 NZ NZ700556A patent/NZ700556A/en unknown
- 2011-03-25 RS RS20210007A patent/RS61314B1/sr unknown
- 2011-03-25 RU RU2015153068A patent/RU2711481C2/ru active
- 2011-03-25 CN CN201810927753.5A patent/CN109081804B/zh active Active
- 2011-03-25 HR HRP20230661TT patent/HRP20230661T1/hr unknown
- 2011-03-25 MX MX2012011062A patent/MX347804B/es active IP Right Grant
- 2011-03-25 PT PT141729913T patent/PT2826776T/pt unknown
- 2011-03-25 EP EP14172991.3A patent/EP2826776B1/fr active Active
- 2011-03-25 ES ES11713134.2T patent/ES2604105T3/es active Active
- 2011-03-25 BR BR112012024338-1A patent/BR112012024338B1/pt active IP Right Grant
- 2011-03-25 EP EP17154840.7A patent/EP3181561B1/fr active Active
- 2011-03-25 SI SI201131935T patent/SI2826776T1/sl unknown
- 2011-03-25 CN CN201610452877.3A patent/CN106083832A/zh active Pending
- 2011-03-25 LT LTEP14172991.3T patent/LT2826776T/lt unknown
- 2011-03-25 EP EP23166117.4A patent/EP4253381A3/fr active Pending
- 2011-03-25 NZ NZ602665A patent/NZ602665A/en unknown
- 2011-03-25 DK DK14172991.3T patent/DK2826776T3/da active
- 2011-03-25 NZ NZ718018A patent/NZ718018A/en unknown
- 2011-03-25 CA CA3016080A patent/CA3016080C/fr active Active
- 2011-03-25 EP EP11713134.2A patent/EP2563778B1/fr active Active
- 2011-03-25 ES ES14172991T patent/ES2845449T3/es active Active
- 2011-03-25 SM SM20210051T patent/SMT202100051T1/it unknown
- 2011-03-25 US US13/072,380 patent/US20110251253A1/en not_active Abandoned
- 2011-03-25 CN CN201180025743.9A patent/CN102892764B/zh active Active
- 2011-03-25 PL PL14172991T patent/PL2826776T3/pl unknown
- 2011-03-25 JP JP2013501522A patent/JP5734410B2/ja active Active
- 2011-03-25 HU HUE14172991A patent/HUE052759T2/hu unknown
- 2011-03-25 EP EP20206423.4A patent/EP3835297B1/fr active Active
- 2011-03-25 MX MX2016001939A patent/MX345541B/es unknown
- 2011-03-25 HU HUE20206423A patent/HUE062892T2/hu unknown
- 2011-03-25 PL PL20206423.4T patent/PL3835297T3/pl unknown
- 2011-03-25 ES ES17154840T patent/ES2804202T3/es active Active
- 2011-03-25 CA CA2794559A patent/CA2794559C/fr active Active
- 2011-03-25 AU AU2011230508A patent/AU2011230508B2/en active Active
- 2011-03-25 MX MX2017001548A patent/MX370904B/es unknown
- 2011-03-25 ES ES20206423T patent/ES2951520T3/es active Active
- 2011-03-25 WO PCT/US2011/030032 patent/WO2011119984A1/fr not_active Ceased
2012
- 2012-09-24 IL IL222117A patent/IL222117B/en active IP Right Grant
2015
- 2015-03-09 JP JP2015046120A patent/JP2015127334A/ja active Pending
2016
- 2016-07-27 AU AU2016208341A patent/AU2016208341B2/en active Active
- 2016-10-20 JP JP2016206062A patent/JP6326570B2/ja active Active
2017
- 2017-12-21 JP JP2017245323A patent/JP6913623B2/ja active Active
2018
- 2018-02-15 IL IL257542A patent/IL257542B/en active IP Right Grant
- 2018-05-07 AU AU2018203149A patent/AU2018203149B2/en active Active
2019
- 2019-10-18 IL IL270047A patent/IL270047B/en unknown
2020
- 2020-03-18 JP JP2020047688A patent/JP6964702B2/ja active Active
2021
- 2021-02-01 HR HRP20210165TT patent/HRP20210165T1/hr unknown
- 2021-02-08 CY CY20211100108T patent/CY1123794T1/el unknown
- 2021-05-14 FR FR21C1018C patent/FR21C1018I2/fr active Active
- 2021-05-14 LT LTPA2021508C patent/LTC2826776I2/lt unknown
- 2021-05-17 HU HUS2100019C patent/HUS2100019I1/hu unknown
- 2021-05-18 LU LU00207C patent/LUC00207I2/en unknown
- 2021-05-19 CY CY2021014C patent/CY2021014I1/el unknown
- 2021-05-21 NO NO2021021C patent/NO2021021I1/no unknown
- 2021-11-25 IL IL288388A patent/IL288388A/en unknown
2023
- 2023-08-03 CY CY20231100390T patent/CY1126143T1/el unknown

Also Published As

Publication number	Publication date
NZ700556A (en)	2016-04-29
CN109081804B (zh)	2021-12-10
ES2604105T3 (es)	2017-03-03
ES2804202T3 (es)	2021-02-04
US20110251253A1 (en)	2011-10-13
IL288388A (en)	2022-01-01
WO2011119984A1 (fr)	2011-09-29
MX2012011062A (es)	2013-01-14
EP2826776B1 (fr)	2020-11-25
CN109081804A (zh)	2018-12-25
EP3835297C0 (fr)	2023-06-07
CY1126143T1 (el)	2023-11-15
MX347804B (es)	2017-05-15
FR21C1018I2 (fr)	2023-02-17
EP3181561A1 (fr)	2017-06-21
CN102892764B (zh)	2016-07-06
RU2573830C2 (ru)	2016-01-27
AU2011230508B2 (en)	2016-04-28
AU2011230508A1 (en)	2012-10-18
EP2826776A1 (fr)	2015-01-21
JP6913623B2 (ja)	2021-08-04
AU2016208341A1 (en)	2016-08-18
CA2794559C (fr)	2019-07-23
LTPA2021508I1 (fr)	2021-06-10
JP6326570B2 (ja)	2018-05-23
EP4253381A2 (fr)	2023-10-04
ES2951520T3 (es)	2023-10-23
AU2018203149B2 (en)	2019-07-25
EP3181561B1 (fr)	2020-05-20
RU2015153068A (ru)	2019-01-17
CN102892764A (zh)	2013-01-23
EP3835297B1 (fr)	2023-06-07
RU2015153068A3 (fr)	2019-07-17
NZ718018A (en)	2017-10-27
AU2018203149A1 (en)	2018-05-24
PL2826776T3 (pl)	2021-05-31
BR112012024338B1 (pt)	2021-09-28
BR112012024338A2 (pt)	2020-09-01
ES2845449T3 (es)	2021-07-26
JP2017008120A (ja)	2017-01-12
CY2021014I2 (el)	2021-10-15
CY2021014I1 (el)	2021-10-15
CN106083832A (zh)	2016-11-09
NO2021021I1 (no)	2021-05-21
JP5734410B2 (ja)	2015-06-17
CA3016080A1 (fr)	2011-09-29
DK2826776T3 (da)	2020-12-14
JP2020094068A (ja)	2020-06-18
JP6964702B2 (ja)	2021-11-10
JP2015127334A (ja)	2015-07-09
RU2012145295A (ru)	2014-04-27
EP3835297A1 (fr)	2021-06-16
SI2826776T1 (sl)	2021-02-26
NZ602665A (en)	2014-10-31
CA2794559A1 (fr)	2011-09-29
IL257542A (en)	2018-04-30
LTC2826776I2 (fr)	2023-12-11
MX370904B (es)	2020-01-09
HRP20210165T1 (hr)	2021-03-19
IL222117B (en)	2018-02-28
EP4253381A3 (fr)	2023-11-01
LT2826776T (lt)	2021-01-11
IL270047B (en)	2022-01-01
EP2563778A1 (fr)	2013-03-06
JP2018048207A (ja)	2018-03-29
AU2016208341B2 (en)	2018-05-24
EP2563778B1 (fr)	2016-08-24
CA3016080C (fr)	2019-08-20
HUE052759T2 (hu)	2021-05-28
CY1123794T1 (el)	2021-09-14
PT2826776T (pt)	2021-02-01
RU2711481C2 (ru)	2020-01-17
HUE062892T2 (hu)	2023-12-28
RS61314B1 (sr)	2021-02-26
JP2013523655A (ja)	2013-06-17
HUS2100019I1 (hu)	2021-06-28
MX345541B (es)	2017-02-03
HRP20230661T1 (hr)	2023-09-29
PL3835297T3 (pl)	2023-09-11
LUC00207I2 (fr)	2024-10-04
IL257542B (en)	2020-05-31
SMT202100051T1 (it)	2021-03-15

Publication	Publication Date	Title
FR21C1018I2 (fr)	2023-02-17	Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide
SMT201600174B (it)	2016-08-31	Forme solide di acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]diossol-5-il)ciclopropancarbossammido)-3-metilpiridin-2-il)benzoico
BRPI0911764A2 (pt)	2015-10-06	inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
DOP2009000202A (es)	2009-09-15	Compuesto anulares fusionados como agonistas parciales de ppar-gamma
DE502008001391D1 (de)	2010-11-04	Heteroaroylsubstituierte serin-amide
HUE043536T2 (hu)	2019-08-28	PDK1 inhibitorként alkalmazható heterociklusos vegyületek
EP2248360A4 (fr)	2012-01-04	Différentiation de tonalité de vibration
PL2349132T3 (pl)	2021-05-17	Aparat do leczenia gerd
BRPI0820689A2 (pt)	2019-09-24	processo de produção de um derivado de indolinona
EP2454227A4 (fr)	2015-09-16	Synthèse de prostanoïdes
EP2373326A4 (fr)	2012-09-05	Formes cristallines de la génistéine
EP2632461A4 (fr)	2014-04-02	Composés d'isoindolinone utiles comme inhibiteurs de pde 10
BR112012002336A2 (pt)	2016-05-31	compostos aza-heterocíclicos
SMT201600031B (it)	2016-02-25	Composti eterociclici di fenossimetile
EP2268635A4 (fr)	2012-02-22	Composés hétérocycliques
IT1392813B1 (it)	2012-03-23	Forme cristalline di dexlansoprazolo
EP2296095A4 (fr)	2011-06-01	Générateur de descripteurs vidéo
EP2383313A4 (fr)	2014-06-25	Encre de marquage
NO20090798L (no)	2010-08-20	Beskyttelsesstruktur for beskyttelse av undersjoisk utstyr
BR112013008049A2 (pt)	2016-06-21	processo de síntese de compostos beta-dicarbonilados
BRPI0923367A2 (pt)	2015-07-21	Gerador de imagem de perfuração com multiplas frequencias
EP2242554A4 (fr)	2012-03-28	Distributeur de descente
EP2509970A4 (fr)	2013-05-08	Dépolymérisation d'éthers cycliques oligomères
IT1394292B1 (it)	2012-06-06	Procedimento per la sintesi di pregabalina
ES1069389Y (es)	2009-06-16	"dispositivo para representacion cromatica del sonido ambiente"